Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients
Clinical Chemistry · 01.09.2023 · 69 (9) · 1050-1061
DOI: 10.1093/clinchem/hvad084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 21.07.2023. Verfasst von Dimo Dietrich und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Cell-Free Nucleic Acids, Head and Neck Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Tumorous SEPT9 (septin 9, SEPTIN9) circulating cell-free DNA (ccfDNA) methylation in blood plasma is a powerful biomarker for diagnosis, molecular staging, prognosis, and recurrence monitoring in head and neck squamous cell carcinoma (HNSCC) patients. The present study aimed to evaluate the clinical performance of SEPT9 ccfDNA methylation to detect post-surgical minimal residual disease (MRD) in patients with localized or locally advanced HNSCC treated with curative intent.
Methods
We applied quasi-digital methylation-specific real-time PCR to quantify SEPT9 ccfDNA methylation levels 2 to 30 days post-surgically in plasma from n = 219 prospectively enrolled HNSCC patients. We tested the associations of SEPT9 ccfDNA methylation with clinicopathological parameters and used Kaplan–Meier and Cox proportional hazards analyses for univariate, pairwise bivariate, and multivariate analyses of disease-free survival.
Results
Of 219 patients, 26.5% (58/219) were post-surgically SEPT9 ccfDNA methylation positive. SEPT9 ccfDNA methylation positivity was significantly associated with tumor site, American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC; 8th edition) tumor stage, nodal category and extracapsular extension, lymphatic and vascular invasion, and surgical margin. Bivariate Cox proportional hazards analysis proved post-surgical SEPT9 ccfDNA methylation positivity to be an independent prognostic factor tested together with AJCC/UICC tumor stage (SEPT9: hazard ratio [HR] = 2.43, 95% CI, 1.37–4.30, P = 0.002; AJCC/UICC stage: HR = 1.48, 95% CI, 1.11–1.98, P = 0.008).
Conclusions
Post-surgical SEPT9 ccfDNA methylation may aid to identify high-risk HNSCC patients who could benefit from an intensified adjuvant treatment and surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany.
- Department of Oral and Maxillofacial Surgery, University Medical Center Bonn (UKB), Bonn, Germany.
- Department of Dermatology and Allergology, University Medical Center Bonn (UKB), Bonn, Germany.
- Department of Oncology, Hematology and Rheumatology, University Medical Center Bonn (UKB), Bonn, Germany.
- Department of Pathology, University Medical Center Bonn (UKB), Bonn, Germany.
ORCID-Profile: Alina Franzen
Zitieren
APA
Dietrich, D., Weider, S., de Vos, L., Vogt, T. J., Färber, M., Zarbl, R., Hunecke, A., Glosch, A. K., Gabrielpillai, J., Bootz, F., Bauernfeind, F. G., Kramer, F. J., Kristiansen, G., Brossart, P., Strieth, S., & Franzen, A. (2023). Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients. Clinical Chemistry, 69(9), 1050-1061. https://doi.org/10.1093/clinchem/hvad084
Vancouver
Dietrich D, Weider S, de Vos L, Vogt TJ, Färber M, Zarbl R, et al. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients. Clinical Chemistry. 2023;69(9):1050-1061. doi:10.1093/clinchem/hvad084
BibTeX
@article{Dietrich2023,
author = {Dietrich, Dimo and Weider, Simone and de Vos, Luka and Vogt, Timo Jakob and Färber, Moritz and Zarbl, Romina and Hunecke, Alina and Glosch, Ann-Kathrin and Gabrielpillai, Jennis and Bootz, Friedrich and Bauernfeind, Franz-Georg and Kramer, Franz-Josef and Kristiansen, Glen and Brossart, Peter and Strieth, Sebastian and Franzen, Alina},
title = {Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients},
journal = {Clinical Chemistry},
year = {2023},
volume = {69},
number = {9},
pages = {1050--1061},
doi = {10.1093/clinchem/hvad084}
}
EUVIMED